These sources of genetic variation within CYP2D6 and genetic polymorphisms across the human genome create the potential to modify the phenotypic AS for probe drugs as well as drugs to treat malaria and other wide-ranging health conditions (implications are focused on PQ discussed in sections below). Here, CYP2D6 is linked to malaria.